QuidelOrtho (QDEL) FY2025 10-K Risk Factors: 7 New, 9 Dropped

What the changes say

Debt remains central: total indebtedness rose to $2.65 billion, while revolver availability was $596.6 million.
AI risk is more specific, adding data provenance, model drift, adaptive algorithms, transparency and third-party model claims.
Cybersecurity, patent challenges, regulatory inspections and internal-control failures are newly emphasized.

What changed since the prior 10-K

New

NewRisks Relating to Our Business, Strategy and Operations
Our collaboration arrangements may not operate according to our business strategy and if we are unable to maintain our collaboration arrangements, or if these collaboration arrangements are not successful, our results of operations could be materially adversely affected
Disagreements with collaboration partners could delay decisions, breach or terminate agreements, or divert strategy through disputes and litigation.
NewRisks Relating to Our IT Systems
incur increased costs from insurance premiums and remediation measures and subject us to potential liability, litigation and regulatory or other government action. If any of the foregoing were to occur, our business strategy, results of operations or financial condition could be materially and adversely affected
Cyberattacks or disruptions affecting QuidelOrtho, collaboration partners or service providers could cause costs, liability, litigation and regulatory action.
NewRisks Relating to Our Intellectual Property
successful in securing additional patents on commercially desirable improvements, that such additional patents will adequately protect our innovations or offset the effect of expiring patents, or that competitors will not be able to design around our patents
Patent claims may be narrowed or canceled through IPR challenges, while changing U.S. and European rules could weaken protection.
NewRisks Relating to Government Regulation
and regulatory restrictions placed upon any such third-party products could have a material adverse impact on the sales or commercial viability of our related products or services
Regulatory inspections and noncompliance involving QuidelOrtho or suppliers could cause fines, recalls, lost approvals, distribution injunctions or criminal prosecution.
NewRisks Relating to Corporate Finance
we had total indebtedness of $2.65 billion, and we had availability under our Revolving Credit Facility of $596.6 million (net of $23.4 million of outstanding letters of credit and $80.0 million borrowings outstanding)
Higher debt, including $2.65 billion outstanding, could constrain financing, acquisitions, cash use and interest-rate resilience.
NewRisks Relating to Our Employees
call a special meeting of the stockholders, unless such stockholders hold at least 50% of our stock entitled to vote at the meeting. These provisions may delay, deter or prevent a change in control of us, adversely affecting the market price of our common stock
Delaware forum requirements and the 50% threshold for special meetings could delay takeovers or limit stockholder litigation options.
NewRisks Relating to Our Employees
If we fail to develop or maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial reporting, which would harm our business and the trading price of our common stock
Weak financial controls could cause inaccurate reporting, fraud, missed Sarbanes-Oxley obligations and loss of investor confidence.

Dropped

DroppedRisks Relating to Our Business, Strategy and Operations
a small number of contract manufacturers and a large number of single and sole source suppliers makes us vulnerable to possible production capacity or other constraints of such suppliers or in their supply chain and reduced control over manufacturing, product availability, delivery schedules and costs
DroppedRisks Relating to Our Business, Strategy and Operations
Our collaboration arrangements may not operate according to our business strategy if our collaboration arrangement partners fail to fulfill their obligations
DroppedRisks Relating to Our Business, Strategy and Operations
Governmental and private healthcare providers and payors around the world are increasingly utilizing managed care for the delivery of healthcare services, forming group purchasing organizations to improve their purchasing leverage and using competitive bid processes to procure healthcare products and services
DroppedRisks Relating to Our Integration and Business Efficiency Efforts
The failure to integrate successfully the businesses of Quidel and Ortho would adversely affect our future business and financial performance
DroppedRisks Relating to Our Integration and Business Efficiency Efforts
We will continue to incur significant integration-related costs in connection with the Combinations
DroppedRisks Relating to Our IT Systems
and services, as well as those of our service providers, remain potentially vulnerable to known or unknown threats. Additionally, our information systems may be vulnerable to damage or interruption from circumstances beyond our control, including fire, natural disasters, power outages and system failures
Dependence on contract manufacturers and single-source suppliers could constrain production, availability, delivery schedules and costs.
DroppedRisks Relating to Government Regulation
clearance or approval, and we may be subject to civil, criminal, monetary and non-monetary penalties and damage to our reputation
DroppedRisks Relating to Government Regulation
or modified products from being developed, cleared, approved or commercialized in a timely manner or at all, which could negatively impact our business
Collaboration partners might fail to fulfill obligations, disrupting the Joint Business with Grifols and strategy.
DroppedRisks Relating to Government Regulation
information, benefits or claims, which is highly regulated by the FTC and the FDA, could be alleged to be misleading or erroneous. If the FTC or the FDA alleges or establishes that any of our communications are misleading, we could be subject to litigation and material penalties and fines

Reworded

88% rewrittenRisks Relating to Corporate Finance
Our indebtedness could adversely affect our financial condition, limit our ability to raise additional capital to fund our operations and prevent us from fulfilling our obligations under our indebtedness
Debt facilities changed to $1.15 billion Term Loan A, $100 million DDTL, $1.45 billion Term Loan B and $700 million revolver.
84% rewrittenRisks Relating to Our Intellectual Property
To remain competitive, we must continue to develop, obtain and protect proprietary technology rights; otherwise, we may lose market share or need to reduce prices as a result of competitors selling lower priced or technologically superior products or services that compete with ours
No substantive change: the risk still centers on developing, protecting or licensing diagnostic technology to remain competitive.
80% rewrittenRisks Relating to Our Employees
Some provisions of our Charter, our Bylaws and Delaware law may make takeover attempts difficult, which could depress the price of our common stock and inhibit our stockholders’ ability to receive a premium price for their shares
The takeover risk is substantially unchanged, with only minor wording changes from acquiring the business to acquiring the Company.
78% rewrittenRisks Relating to Our Business, Strategy and Operations
Interruptions and delays in the supply of raw materials, components, equipment and other products and services could adversely affect our operations and financial results
No substantive change: third-party supply, logistics, distribution, labor and raw-material disruptions remain the focus.
70% rewrittenRisks Relating to Our Employees
We are subject to work stoppages, union negotiations, labor disputes and other matters associated with our labor force, which may adversely impact our operations and cause us to incur incremental costs
Reported employees declined from approximately 6,600 to 6,500, while union, work-stoppage and labor-dispute risks remained otherwise unchanged.
70% rewrittenRisks Relating to Our Business, Strategy and Operations
We have been incorporating AI into our internal operations and may incorporate AI into our products and services. Implementation of AI and machine learning technologies may result in legal and regulatory risks, reputational harm or have other adverse consequences to our business
AI risks now specifically include data provenance, consent, model bias and drift, adaptive-algorithm governance, transparency, monitoring and third-party claims.
62% rewrittenRisks Relating to Our Business, Strategy and Operations
Consolidation of our customer base, the formation of group purchasing organizations and government-sponsored tendering processes could materially adversely affect our sales and results of operations
The risk now expressly includes pricing pressure and contract terms in tendering or contracting processes, not only tendering.
55% rewrittenRisks Relating to Our Business, Strategy and Operations
Fluctuations or a decline in sales of our respiratory products could materially and adversely affect our operating results
Respiratory products fell from 18% to 15% of revenue, with demand language expanded to disease spread, severity, duration and new variants.
51% rewrittenRisks Relating to Our Business, Strategy and Operations
The healthcare industry and related industries that we serve have undergone, and are in the process of undergoing, significant changes, including staffing constraints and efforts to reduce costs, which could adversely affect our business, financial condition and results of operations
Was: The healthcare industry and related industries that we serve have undergone, and are in the process of undergoing, significant changes, including an effort to reduce costs, which could adversely affect our business, financial condition and results of operations
50% rewrittenRisks Relating to Our IT Systems
Our ability, or that of our providers or third-party collaboration partners, to protect our information systems in our IT and product systems, and personal and confidential information, including from data corruption, cyber-attacks, security breaches or IT errors, is critical to the success of our business
Was: Our ability to protect our information systems and personal and confidential information, including from data corruption, cyber-attacks, security breaches or IT errors, is critical to the success of our business
46% rewrittenRisks Relating to Government Regulation
If one or more of our products is claimed to be defective or does not comply with applicable regulations, we could be subject to claims of liability and harm to our reputation that could adversely affect our business
41% rewrittenRisks Relating to Government Regulation
If the results of clinical studies required to gain regulatory approval to sell our products are not available when expected, or do not demonstrate the safety and effectiveness of those products, we may be unable to obtain regulatory approval and sell those products
37% rewrittenRisks Relating to Our Employees
If we are required to make unexpected payments to any defined benefit plans or other post-employment benefit plans (“Benefit Plans”) applicable to our employees, our financial condition may be adversely affected
34% rewrittenRisks Relating to Government Regulation
If we are unable to obtain or maintain required clearances or approvals for the commercialization of our products in the U.S. and certain foreign countries where we intend to sell our products, we will not be able to sell those products in such jurisdictions, which could negatively impact our results of operations
Was: If we are unable to obtain or maintain required clearances or approvals for the commercialization of our products in the U.S. and certain foreign countries, we will not be able to sell those products in such jurisdictions, which could negatively impact our results of operations
32% rewrittenRisks Relating to Our International Operations
As a global business, we face risks relating to our non-U.S. operations and international sales, including inherent macroeconomic, geopolitical and regulatory risks, that could impact our financial performance, cause interruptions in our current business operations and impede our growth strategy
31% rewrittenRisks Relating to Our Employees
Expectations of our performance related to sustainability matters, or the reporting of such matters, may impose additional costs on us and expose us to new risks
28% rewrittenRisks Relating to Our Employees
We may have difficulty attracting, motivating and retaining executives and other key employees
27% rewrittenRisks Relating to Government Regulation
Some of our respiratory products were authorized by the FDA through an EUA and the loss of such authorization could have a material adverse effect on our business, results of operations, financial position and cash flows
22% rewrittenRisks Relating to Our IT Systems
Interruptions to our third-party IT service providers and/or the inability of our digital solutions to interoperate with certain operating systems could impair the delivery of our cloud-based solutions and negatively impact our business
21% rewrittenRisks Relating to Government Regulation
We are subject to U.S. and foreign tax laws, and changes to such tax laws or differing interpretation of those laws by the relevant governmental authorities could adversely affect us

All 47 risk factors

Headings as the filing states them, in filing order.

Risks Relating to Our Business, Strategy and Operations

01The industry and market segments in which we operate are highly competitive, and our failure to compete effectively could adversely affect our sales and results of operations
02Global market, macroeconomic and geopolitical conditions may adversely affect our operations and performance
03Fluctuations or a decline in sales of our respiratory products could materially and adversely affect our operating results55% rewritten
04A significant portion of our total revenues are from a relatively small number of customers, and if we fail to retain or expand our customer relationships or significant customers terminate or do not renew their contracts, our business, operating results and financial condition could be adversely affected
05Interruptions and delays in the supply of raw materials, components, equipment and other products and services could adversely affect our operations and financial results78% rewritten
06We may experience manufacturing or warehousing problems or delays due to, among other reasons, our volume, specialized processes, natural disasters, public health crises and macroeconomic and geopolitical conditions
07Our collaboration arrangements may not operate according to our business strategy and if we are unable to maintain our collaboration arrangements, or if these collaboration arrangements are not successful, our results of operations could be materially adversely affectedNew
08A decrease in the number of surgical procedures performed, and the resulting decrease in blood demand, could negatively impact our financial results
09Our reagent rental model reduces our cash flows during the initial part of the applicable contract, which causes our cash flows to fluctuate from quarter to quarter
10We may not achieve anticipated market acceptance of our products by customers and this would have a negative effect on future sales
11The healthcare industry and related industries that we serve have undergone, and are in the process of undergoing, significant changes, including staffing constraints and efforts to reduce costs, which could adversely affect our business, financial condition and results of operations51% rewritten
12Consolidation of our customer base, the formation of group purchasing organizations and government-sponsored tendering processes could materially adversely affect our sales and results of operations62% rewritten
13We have been incorporating AI into our internal operations and may incorporate AI into our products and services. Implementation of AI and machine learning technologies may result in legal and regulatory risks, reputational harm or have other adverse consequences to our business70% rewritten

Risks Relating to Our International Operations

14As a global business, we face risks relating to our non-U.S. operations and international sales, including inherent macroeconomic, geopolitical and regulatory risks, that could impact our financial performance, cause interruptions in our current business operations and impede our growth strategy32% rewritten
15Currency translation risk and currency transaction risk may adversely affect our financial condition, results of operations and cash flows

Risks Relating to Our IT Systems

16Our ability, or that of our providers or third-party collaboration partners, to protect our information systems in our IT and product systems, and personal and confidential information, including from data corruption, cyber-attacks, security breaches or IT errors, is critical to the success of our business50% rewritten
17incur increased costs from insurance premiums and remediation measures and subject us to potential liability, litigation and regulatory or other government action. If any of the foregoing were to occur, our business strategy, results of operations or financial condition could be materially and adversely affectedNew
18Interruptions to our third-party IT service providers and/or the inability of our digital solutions to interoperate with certain operating systems could impair the delivery of our cloud-based solutions and negatively impact our business22% rewritten

Risks Relating to Our Intellectual Property

19To remain competitive, we must continue to develop, obtain and protect proprietary technology rights; otherwise, we may lose market share or need to reduce prices as a result of competitors selling lower priced or technologically superior products or services that compete with ours84% rewritten
20successful in securing additional patents on commercially desirable improvements, that such additional patents will adequately protect our innovations or offset the effect of expiring patents, or that competitors will not be able to design around our patentsNew

Risks Relating to Government Regulation

21Regulation of Our Industry and Products
22Some of our respiratory products were authorized by the FDA through an EUA and the loss of such authorization could have a material adverse effect on our business, results of operations, financial position and cash flows27% rewritten
23If we are unable to obtain or maintain required clearances or approvals for the commercialization of our products in the U.S. and certain foreign countries where we intend to sell our products, we will not be able to sell those products in such jurisdictions, which could negatively impact our results of operations34% rewritten
24If the results of clinical studies required to gain regulatory approval to sell our products are not available when expected, or do not demonstrate the safety and effectiveness of those products, we may be unable to obtain regulatory approval and sell those products41% rewritten
25and regulatory restrictions placed upon any such third-party products could have a material adverse impact on the sales or commercial viability of our related products or servicesNew
26We may encounter challenges entering into contracts with government entities due to government-sponsored tendering requirements, and any contracts that we have entered into or will enter into with government entities may involve future funding, compliance and penalties risks
27If one or more of our products is claimed to be defective or does not comply with applicable regulations, we could be subject to claims of liability and harm to our reputation that could adversely affect our business46% rewritten
28We are subject to healthcare laws and regulations that could result in liability, require us to change our business practices and restrict our operations in the future
29We use hazardous materials in our business that may result in substantial compliance costs or claims against us relating to handling, storage or disposal
30We are exposed to significant risks in relation to compliance with anti-bribery and anti-corruption laws and regulations and economic sanctions programs
31We are subject to U.S. and foreign tax laws, and changes to such tax laws or differing interpretation of those laws by the relevant governmental authorities could adversely affect us21% rewritten

Risks Relating to Corporate Finance

32We may need to raise additional funds to finance our future capital or operating needs or other business purposes, which could have adverse consequences on the interests of our stockholders, and may not be available on acceptable terms or at all
33Our indebtedness could adversely affect our financial condition, limit our ability to raise additional capital to fund our operations and prevent us from fulfilling our obligations under our indebtedness88% rewritten
34we had total indebtedness of $2.65 billion, and we had availability under our Revolving Credit Facility of $596.6 million (net of $23.4 million of outstanding letters of credit and $80.0 million borrowings outstanding)New
35The occurrence of any one of the foregoing risks could have a material adverse effect on our business, financial condition, results of operations and ability to satisfy our obligations in respect of our outstanding debt
36Our inability to generate sufficient cash flows to satisfy our debt obligations, or to refinance our indebtedness on commercially reasonable terms or at all, would materially and adversely affect our business, financial position and results of operations and our ability to satisfy our debt obligations

Risks Relating to Our Employees

37We may have difficulty attracting, motivating and retaining executives and other key employees28% rewritten
38If we are required to make unexpected payments to any defined benefit plans or other post-employment benefit plans (“Benefit Plans”) applicable to our employees, our financial condition may be adversely affected37% rewritten
39We are subject to work stoppages, union negotiations, labor disputes and other matters associated with our labor force, which may adversely impact our operations and cause us to incur incremental costs70% rewritten
40We are subject to, and may in the future become subject to, disputes, claims and litigation that could result in significant expenses and could ultimately result in an unfavorable outcome for us
41Expectations of our performance related to sustainability matters, or the reporting of such matters, may impose additional costs on us and expose us to new risks31% rewritten
42We are exposed to business risk which, if not fully covered by insurance, could have an adverse effect on our results of operations
43Some provisions of our Charter, our Bylaws and Delaware law may make takeover attempts difficult, which could depress the price of our common stock and inhibit our stockholders’ ability to receive a premium price for their shares80% rewritten
44call a special meeting of the stockholders, unless such stockholders hold at least 50% of our stock entitled to vote at the meeting. These provisions may delay, deter or prevent a change in control of us, adversely affecting the market price of our common stockNew
45The market price of our common stock may be volatile
46Future sales of our common stock by us or our stockholders in the public market, or the perception that such sales may occur, could reduce the price of our common stock, and any additional capital raised by us through the sale of equity or convertible securities may dilute ownership in the Company
47If we fail to develop or maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial reporting, which would harm our business and the trading price of our common stockNew

Other QuidelOrtho 10-Ks

FY2024 10-K risk factors
49 risks
QuidelOrtho faces high debt burdens, integration risks from combining Quidel and Ortho, and heavy reliance on volatile respiratory product sales.
Filed Feb 27, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.